Latest Pharmaceutical News
Dainippon Sumitomo Pharma America Gets FDA Nod For Lurasidone
Dainippon Sumitomo Pharma America, a US subsidiary of Dainippon Sumitomo Pharma (DSP), has reported that the FDA has accepted for review the lurasidone new drug application (NDA) for the treatment of patients with acute schizophrenia.
Published: 11-Mar-2010
Salix Pharma Q4 Net Loss Narrows
Salix Pharma has reported a net loss of $7.02m, or $0.13 per diluted share, for the fourth quarter ended December 31, 2009, compared to $11.07m, or $0.23 per diluted share, for the comparable period in 2008.
Published: 10-Mar-2010
Abbott To Acquire Facet Biotech
Abbott has agreed to acquire Facet Biotech for $27 per share in cash for a net transaction value of approximately $450m to enhance its early- and mid-stage pharmaceutical pipeline.
Published: 10-Mar-2010
Nordlund Centre For Biomedical Structural Biology Purchases Maybridge Ro3 500 Fragment Library
Maybridge, a part of Thermo Fisher Scientific, has said that the Nordlund Centre for Biomedical Structural Biology (Nordlund) at Nanyang Technological University in Singapore has purchased its Ro3 500 Fragment Library.
Published: 10-Mar-2010
Sanofi-aventis To Combine Merial With Merck Intervet/Schering-Plough
Sanofi-aventis has exercised its option to combine Merial with Merck’s animal health business Intervet/Schering-Plough to create a global player in animal health. The new joint venture would be equally-owned by Merck and sanofi-aventis.
Published: 09-Mar-2010
Teijin Pharma Launches Febuxostat To Manage Hyperuricemia In Gout Patients
Teijin Pharma has launched TMX-67 (febuxostat) in Europe for the treatment of hyperuricemia in patients with gout.
Published: 09-Mar-2010
ExonHit Therapeutics, bioMerieux To Terminate Colon Cancer Collaboration
ExonHit Therapeutics (ExonHit) and bioMerieux have decided not to pursue their collaboration in colon cancer, following a recent review of data by their scientific committee.
Published: 08-Mar-2010
Opexa FY09 Net Loss Narrows
Opexa Therapeutics, a bio-pharmaceutical company, has reported a net loss of $1.43m, or $0.11 per diluted share, for the full year ended December 31, 2009, compared to $11.85m, or $1.12 per diluted share, in 2008.
Published: 08-Mar-2010
Sigma Life Science Launches New Suite Of Rat Models
Sigma Life Science, a brand of Sigma-Aldrich, has extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.
Published: 08-Mar-2010
MitoTarget Consortium Launches Web-based Resource For ALS Patients
Trophos, a pharma company specialising in therapies for orphan diseases including ALS, has launched MitoTarget Online, on behalf of the MitoTarget consortium.
Published: 08-Mar-2010
